80% success chance for Oxford trials-THE HINDU-23-04-2020
Poonawalla, whose family owns the vaccine maker, said scientists, drugmakers and manufacturers were collaborating at an unparalleled scale to spur development and availability.
WHO backs COVID-19 vaccine trials that deliberately infect participants.
Serum has partnered with U.S The United States has secured almost a third of the first 1 billion doses planned for the potential vaccine, initially known as ChAdOx1 and now as AZD1222, by pledging up to USD1.2 billion. “Hopefully we will build a stock of a few million doses to give to our country and other high-risk areas across the globe come October-November when the trials ought to be concluded,” the 39-year-old said.
He had been given to understand by the development team that the trials had an 80% chance of success, given that the vaccine is based on a tried-and-tested platform. Based on the information currently available, he said he anticipated AZD1222 would be a single-dose vaccine and not require a booster dose.